Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 68% · stale
- Computed at
- 2026-08-20T10:56:12.656804+00:00
- Claimed
- 100
- Reported
- 86
- Verified
- 72
- Gap
- +28
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Adopt with guardrails
- Why
- Category-defining and commercially dominant (~$45B projected 2026 run-rate, first dual GIP/GLP-1 agonist approved for obesity) but real guardrails remain: inconsistent insurance/Medicaid coverage, a patent-protected monopoly until 2036, and an FDA-driven shutdown of cheaper compounded alternatives tied to hundreds of documented adverse events
- Next
- Track the 2036 tirzepatide patent-cliff/generic timeline, the outcome of the FDA's 503B compounding-ban proposal, and successor next-gen incretins (e.g., retatrutide, oral GLP-1/GIP agents) for follow-on register entries
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 6
- Tier 3
- 0
- Supports
- 3
- Contradicts
- 2
- Context
- 1
- Latest observed
- 2026-07-01
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-08-20 Reading moved from ready to ready.